Major boost for Lupin as USFDA grants tentative approval for generic Siponimod multiple sclerosis drug.

Reinforcing its global generic leadership, Lupin's latest USFDA nod for Siponimod strengthens its commitment to critical treatments.

Secured just recently, Lupin's USFDA tentative approval for Siponimod significantly paves the way for future patient access to MS treatment.

For more news on stock markets visit our website www.stockmarkets.co.in